Milestone® Pharmaceuticals Notice of Allowance on New U.S. Patent for Etripamil
Milestone’s NDA for CARDAMYST is currently under review at the FDA with a Prescription Drug User Fee Act (PDUFA) target date of March 27, 2025. The Company continues to advance commercial preparations ...
Investing3d
Milestone Pharmaceuticals secures key patent for CARDAMYST
This patent pertains to the repeat dose regimen of CARDAMYST™, which demonstrated efficacy in the RAPID Phase 3 study for paroxysmal supraventricular tachycardia (PSVT). The issuance of this ...
Morningstar3d
Milestone® Pharmaceuticals Notice of Allowance on New U.S. Patent for Etripamil
It is a novel calcium channel blocker nasal spray under clinical development for frequent and often highly symptomatic episodes of PSVT and AFib-RVR. It is designed as a self-administered rapid ...
Yahoo Finance4d
Milestone Pharmaceuticals Inc. (MIST)
PDUFA date of March 27, 2025 for CARDAMYST™ (etripamil) nasal spray for Paroxysmal Supraventricular Tachycardia (PSVT ... to initiate Phase 3 Study in AFib-RVR in H1 2025 MONTREAL and CHARLOTTE ...
Investing3d
Milestone Pharmaceuticals secures key patent for CARDAMYST
This patent pertains to the repeat dose regimen of CARDAMYST™, which demonstrated efficacy in the RAPID Phase 3 study for paroxysmal supraventricular tachycardia ... with PSVT and atrial fibrillation ...
WJHG4d
New Procedure for AFib Treatment comes to HCA Florida Fort Walton Beach Destin
PANAMA CITY, Fla. (WJHG/WECP) -According to doctors at HCA Florida Fort Walton Destin, atrial fibrillation, or afib, is an irregular and sometimes rapid heartbeat rhythm. This can lead to blood ...